Boehringer's survodutide passes heart-safety test, heads for regulators

Boehringer Ingelheim's survodutide didn't raise the risk of major cardiovascular events in a Phase III trial, hitting its primary endpoint and clearing the way for regulatory filings. The study, SYNCHRONIZE-CVOT, tested the dual glucagon/GLP-1 receptor agonist in adults living with obesity or overweight who also had established cardiovascular disease, chronic kidney disease and/or at least two weight-related complications or CVD risk factors. Boehringer says it is the first and only global cardiovascular safety trial of a dual glucagon/GLP-1RA.

Full results were presented at the American Heart Association's Scientific Sessions 2026 in Chicago, which ran from 6 to 9 November. The trial's 5P-MACE composite — cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary revascularisation and heart failure events — showed no added risk versus placebo. The key secondary endpoint told the same story: survodutide did not increase 3P-MACE, the combination of cardiovascular death, non-fatal stroke and non-fatal heart attack.

The drug posted gains on cardiometabolic markers too. Systolic blood pressure fell by up to 6.68mmHg at 72 weeks, against 1.76mmHg for people on placebo. High-sensitivity C-reactive protein, an inflammatory marker, and triglycerides both dropped versus placebo — two measures that predict cardiovascular risk. Weight loss reached up to 13.7% at week 72, compared with 2% in the placebo arm.

Side effects landed where the field expects them for GLP-1RA therapies: the gut. Treatment discontinuations due to gastrointestinal adverse events hit 19.3% at the 3.6mg dose and 20.8% at 6.0mg, versus 1.9% on placebo. Boehringer said most dropout happened during dose escalation, when the original protocol allowed only limited flexibility to slow titration, adjust the dose or pause treatment for longer.

The broader SYNCHRONIZE programme backs the filing push. SYNCHRONIZE-1, in adults with overweight or obesity without type 2 diabetes, delivered average sustained weight loss of up to 16.6% at 76 weeks, against 3.2% for placebo. In SYNCHRONIZE-2, which enrolled patients with overweight or obesity plus type 2 diabetes, participants lost an average 13.1% versus 3.1% on placebo, with HbA1c reductions of up to 1.21%. The programme also includes a study in metabolic dysfunction-associated steatotic liver disease, while LIVERAGE and LIVERAGE-Cirrhosis are testing survodutide in MASH with fibrosis stages 2 or 3 and in compensated MASH cirrhosis.

Dr Biykem Bozkurt, the trial's principal investigator, said the challenge in obesity goes past the scale. Combined with the breadth of evidence from the SYNCHRONIZE programme, the data give physicians confidence in managing obesity and related cardiometabolic risk, she said. The market at stake is enormous: GlobalData valued the total obesity market at $34.6bn in 2025 across the seven major markets, with the US holding 82.6% of it, and forecasts growth to $118.2bn by 2035. In Q3 2026, Eli Lilly's tirzepatide sales — sold as Mounjaro and Zepbound — were higher on their own than the full quarterly takings of some big pharma companies, with Lilly and Novo Nordisk leading the sector.